R Squared Ltd Reduces AbbVie Inc. Stake

Hedge fund lowers position in pharmaceutical giant by 85.4% in Q3

Mar. 3, 2026 at 12:47am

Got story updates? Submit your updates here. ›

According to a recent 13F filing, R Squared Ltd lowered its stake in AbbVie Inc. (NYSE:ABBV) by 85.4% in the third quarter. The fund now owns 1,516 shares of the company's stock, down from 10,376 shares previously.

Why it matters

AbbVie is a major pharmaceutical company known for blockbuster drugs like Humira. Tracking changes in institutional ownership can provide insights into how the investment community views the company's prospects.

The details

R Squared Ltd sold 8,860 shares of AbbVie during the third quarter, reducing its position to just 1,516 shares. The fund's holdings in AbbVie were valued at $351,000 at the end of the quarter.

  • R Squared Ltd lowered its AbbVie stake in the third quarter of 2026.

The players

R Squared Ltd

A hedge fund that previously held a larger position in pharmaceutical company AbbVie Inc.

AbbVie Inc.

A global biopharmaceutical company focused on developing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in R Squared Ltd's AbbVie stake suggests the fund may have a less bullish outlook on the pharmaceutical company's prospects compared to previous quarters. However, without additional context, it's difficult to draw firm conclusions about the fund's long-term views on AbbVie.